Pharmacological Management of Central Post‑Stroke Neuropathic Pain
Diagnostic Confirmation
- Pain that begins after a cerebrovascular event and is localized to the neuroanatomical region of the stroke lesion should be confirmed, while nociceptive and peripheral neuropathic sources must be excluded. Characteristic sensory disturbances include burning sensations, allodynia, cold‑induced pain, and dysesthesia. Onset typically occurs within days to one month after the stroke. 1
- Treatment response should be tracked with standardized instruments such as pain diaries, visual analogue scales, or validated pain questionnaires. 1
First‑Line Pharmacologic Therapy
- Amitriptyline 75 mg taken at bedtime is recommended as the primary agent for central post‑stroke pain, based on the strongest evidence from the American Heart Association guidelines; it reduces daily pain intensity and improves overall functional status. 1
Alternative First‑Line Options
- Gabapentin or pregabalin are endorsed by Canadian clinical guidelines as alternatives when amitriptyline is contraindicated or poorly tolerated. 2
- Pregabalin shows mixed efficacy for pain reduction but consistently improves sleep quality and anxiety symptoms. 1
- Gabapentin lacks stroke‑specific trial data yet is effective for other neuropathic pain conditions, supporting its use by extrapolation. 1
Second‑Line Pharmacologic Options
- Lamotrigine can lower daily pain scores and diminish cold‑induced pain, but only about 44 % of patients achieve a good clinical response, indicating modest efficacy. 1
- Serotonin‑norepinephrine reuptake inhibitors (SNRIs), particularly duloxetine, are recommended as second‑line agents when first‑line drugs fail or are not tolerated. 2
Third‑Line / Refractory Management
- Opioids (including tramadol) may be employed for patients with pain refractory to multiple prior agents; however, there is a significant risk of physical dependence, so use should be highly restricted and reserved for those who have exhausted other options. 2
Non‑Pharmacologic Adjuncts
- Integrate therapeutic exercise and psychosocial support with medication, as advised by the American Heart Association, to address the multidimensional nature of central post‑stroke pain. 1
- Implement an interdisciplinary team approach that includes mental‑health specialists and central pain experts to manage comorbid depression, anxiety, and sleep disturbances. 2
Interventional Therapy for Intractable Pain
- Motor cortex stimulation is a viable option for patients with pain unresponsive to pharmacotherapy; it yields ≥50 % pain reduction in 50‑83 % of carefully selected individuals, with benefits lasting up to two years. Notable risks include infection, hardware malfunction, postoperative seizures, and the potential development of long‑term epilepsy. 1
Pitfalls and Contraindicated Interventions
- Transcutaneous electrical nerve stimulation (TENS) has demonstrated no analgesic benefit in small trials and should not be used for central post‑stroke pain. 1
- Avoid diagnostic delays by actively screening for central pain rather than attributing new‑onset pain to musculoskeletal or visceral sources; ensure exclusion of other post‑stroke pain etiologies such as hemiplegic shoulder pain or spasticity‑related discomfort. 1
Monitoring and Treatment Adjustment
- Therapy should be individualized based on specific pain characteristics, comorbid conditions, and observed response; serial standardized assessments are essential for objective tracking. Recognize that complete pain resolution is uncommon, and partial relief often represents a realistic therapeutic goal. 1
Management of Post-Stroke Pain Syndrome
Diagnosis and Assessment
- The American Heart Association recommends that diagnosis of central post-stroke pain should be based on established criteria: pain occurring after stroke, located in an area corresponding to the central nervous system lesion, and not attributable to nociceptive or peripheral neuropathic causes 3, 4
- The incidence of central post-stroke pain is estimated at 7-8%, typically beginning within a few days after stroke, with most patients becoming symptomatic within the first month 3, 4
- Response to treatment should be monitored using standardized serial measurements such as pain diaries, visual analog scales, or pain questionnaires 3, 5
Pharmacological Management Algorithm
- The American Academy of Neurology recommends amitriptyline 75 mg at bedtime as a first-line treatment, which has been shown to lower daily pain ratings and improve global functioning 3, 5
- Lamotrigine can reduce daily pain ratings and cold-induced pain, though only 44% of patients have a good clinical response 3, 5
- Pregabalin has mixed results for pain but may improve sleep and anxiety 3, 5
- Gabapentin has limited studies for post-stroke pain specifically but is effective in other neuropathic pain conditions 3, 5
Non-Pharmacological Options
- Interprofessional pain management in conjunction with pharmacotherapy is recommended by the American Pain Society 3, 5
- TENS (transcutaneous electrical nerve stimulation) is not effective and should not be used 3, 5
- Motor cortex stimulation might be reasonable for intractable central post-stroke pain not responsive to other treatments in carefully selected patients, achieving pain reductions >50% in 50-83% of patients for up to 2 years 3, 5
Comprehensive Management Approach
- Pharmacotherapy should be combined with therapeutic exercise and psychosocial support, as recommended by the American Heart Association 3, 5
- Treatment should be individualized based on patient's specific pain characteristics, comorbidities, and response to therapy 3, 5